InsiderTrades

Form 4 for BIIB Biogen

Accepted 2026-02-10 00:00:00 ET · period of report 2026-02-06 · accession 0000875045-26-000022 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2026-02-10 2026-02-06 BIIB Murphy Nicole Head of Pharm Ops, Tech F - Tax $201.18 -3,339 15.3K -18% -$671.7K
DM 2026-02-10 2026-02-06 BIIB Murphy Nicole Head of Pharm Ops, Tech M - OptEx $0.00 +8,725 21.0K +71% $0
DM 2026-02-10 2026-02-06 BIIB Murphy Nicole Head of Pharm Ops, Tech M - OptEx $0.00 -8,725 9,367 -48% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-02-06 F D 1,408 $201.18 19,608.04 D — —
2 Common Common Stock 2026-02-06 F D 914 $201.18 16,333.04 D — —
3 Common Common Stock 2026-02-06 M A 1,940 $0.00 17,247.04 D — —
4 Common Common Stock 2026-02-06 F D 1,017 $201.18 15,307.04 D — —
5 Common Common Stock 2026-02-06 M A 2,102 $0.00 16,324.04 D — — (F1) Includes 166.6667 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2025.
6 Common Common Stock 2026-02-06 M A 4,683 $0.00 21,016.04 D — —
7 Derivative Restricted Stock Unit 2026-02-06 M D 2,102 $0.00 0 D $0.00 · — to 2026-02-08 2,102 Common Stock (F2) The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023.
8 Derivative Restricted Stock Unit 2026-02-06 M D 1,940 $0.00 1,940 D $0.00 · — to 2027-02-07 1,940 Common Stock (F3) The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024.
9 Derivative Restricted Stock Unit 2026-02-06 M D 4,683 $0.00 9,367 D $0.00 · — to 2028-02-06 4,683 Common Stock (F4) The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025.